2020
DOI: 10.1016/j.jacc.2020.08.044
|View full text |Cite
|
Sign up to set email alerts
|

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
210
3
15

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 510 publications
(229 citation statements)
references
References 297 publications
1
210
3
15
Order By: Relevance
“…Patients carrying mutations in other sarcomere genes were omitted. Left ventricular outflow tract (LVOT) obstruction was defined as maximal left ventricular outflow tract gradient ≥ 30 mmHg either at rest or during provocations such as Valsalva maneuver or bicycle stress testing [18]. Septal reduction therapy was defined as either surgical myectomy or percutaneous transluminal septal myocardial ablation (PTSMA).…”
Section: Clinical Characteristics and Medical Historymentioning
confidence: 99%
“…Patients carrying mutations in other sarcomere genes were omitted. Left ventricular outflow tract (LVOT) obstruction was defined as maximal left ventricular outflow tract gradient ≥ 30 mmHg either at rest or during provocations such as Valsalva maneuver or bicycle stress testing [18]. Septal reduction therapy was defined as either surgical myectomy or percutaneous transluminal septal myocardial ablation (PTSMA).…”
Section: Clinical Characteristics and Medical Historymentioning
confidence: 99%
“…A principal goal of treating symptomatic patients with oHCM is to alleviate their symptoms so as to improve their function and quality of life. 6 The recent 2020 American Heart Association/American College of Cardiology professional treatment guidelines for patients with HCM identified a clear unmet need for novel trial designs and patient-reported outcome tools to assess the impact of new therapies on meaningful endpoints, such as quality of life. Evidence supporting the health status benefits of alternative therapeutic approaches was limited and the benefits of direct myosin modulation were not available.…”
Section: Discussionmentioning
confidence: 99%
“…For example, the intended reduction in ejection fraction with a direct myosin inhibitor resulted in some patients having a transient ejection fraction below 50%, but the KCCQ benefits in these patients were still substantial. Such work is especially important given that the recent guidelines emphasize the importance of shared medical decision making 6 and it would be important to be able to explain to patients how treatment with mavacamten would be expected to improve their health status.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…La American Heart Association publica una guía clínica de miocardiopatía hipertrófica 3 cuyo aspecto pediátrico más importante hace referencia a la estratificación del riesgo de muerte súbita (MS) y la recomendación de implante de desfibrilador automático implantable, siempre una indicación muy individualizada en pediatría. Aunque los autores remarcan la existencia de escalas pediátricas predictoras de riesgo, reconocen que aún no están validadas en la clínica.…”
Section: Cardiología Pediátricaunclassified